Multaq
Jul
22
Editor Emeritus on July 22nd, 2011
The US FDA notified healthcare professionals that it is reviewing data from a clinical trial that evaluated the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial fibrillation. The study was stopped early after the data monitoring committee found a two-fold increase in death, as well as two-fold increases in stroke and […]
Continue reading about Multaq (dronedarone): Another Approved Drug Found To Be Dangerous